N8 Medical submits IDE app seeking 1st-in-human trial of CeraShield endotracheal tube

N8 Medical said today it submitted an investigational device exemption application to the FDA for a first-in-human study of its CeraShield endotracheal tube. The Dublin, Ohio-based company’s CeraShield ETT is a ceragenin-coated ETT designed to prevent the growth of biofilms and reduce potential for infection for intubated patients. “We are looking forward to bringing our breakthrough CeraShield endotracheal tube device to patients and hospitals that we believe will realize a substantial benefit,” prez &COO Ronald Bracken said in prepared remarks. N8 said it is hopeful it will be able to initiate human clinical trials in the US during the first quarter of this year after it receives IDE approval. “We are pleased that FDA designated the CeraShield ETT as a breakthrough device in light of its life-saving potential, and we are also thankful that the NIH, NIAID and CDC provided valuable testing services that have enabled us to reach this important milestone,” CEO Carl Genberg said in a press release. The post N8 Medical submits IDE app seeking 1st-in-human trial of CeraShield endotracheal tube appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Food & Drug Administration (FDA) Respiratory n8medical Source Type: news

Related Links:

V. Kalidasan, Narcisse Joseph, Suresh Kumar, Rukman Awang Hamat, Vasantha Kumari Neela
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Mohammad Khalid Zakaria, Tea Carletti, Alessandro Marcello
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Anna-Maria Dietl, Ulrike Binder, Yana Shadkchan, Nir Osherov, Hubertus Haas
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Maarten G. K. Ghequire, Ba şak Öztürk, René De Mot
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Carolina Escobar Rodr íguez, Birgit Mitter, Livio Antonielli, Friederike Trognitz, Stéphane Compant, Angela Sessitsch
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Dong-Shan Yu, Tian-Hao Weng, Chen-Yu Hu, Zhi-Gang Wu, Yan-Hua Li, Lin-Fang Cheng, Nan-Ping Wu, Lan-Juan Li, Hang-Ping Yao
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Lei Liu, Ruiyun Wu, Jinlan Zhang, Pinglan Li
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Publication date: Available online 12 November 2018Source: Journal of Microbiological MethodsAuthor(s): Yu-Ke Cen, Jian-Guang Lin, Jun-You Wang, Zhi-Qiang Liu, Yu-Guo ZhengAbstractA colorimetric assay has been developed for quantitative analysis of active biomass of Fusarium fujikuroi, based on the reduction of the tetrazolium salt 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) when menadione was present as an electron coupling agent. The optimum assay-conditions were set as 200 μg/ml XTT, 5 μM menadione and one-hour reaction time. Under these settings, the produced formazan displa...
Source: Journal of Microbiological Methods - Category: Microbiology Source Type: research
In this study, we developed a suspension array that can accurately diagnose and identify 19 different P. aeruginosa O-antigen serotypes except O15, whose O-antigen gene cluster has not been characterized. In this assay, wzx/wzy genes were selected as the sero-specific gene for 18 serotypes other than O6, for which the glycosyltransferase gene wbpP was utilized. Meanwhile, the wzyβ gene was added to separate O2/16 from O5/18/20, and the insertion sequence (IS) in wzx was used to separate O17 from O11. Eighty-two clinical isolates were screened to test our assay. A total of 65 isolates (79.3%) could be serotyped, and th...
Source: Journal of Microbiological Methods - Category: Microbiology Source Type: research
Publication date: Available online 12 November 2018Source: Journal of Microbiological MethodsAuthor(s): Cesira Giordano, Simona BarniniAbstractCarbapenemase-producing Klebsiella pneumoniae has become a worldwide recognized cause of nosocomial infections and requires urgent public health attention. The main reason of this concern is the increasing resistance to all the last-resort antibiotics, including colistin. The ideal methodology for colistin susceptibility testing still remains undefined. However, the emergence of colistin as one of the last-option treatments requires a reliable method to determine the susceptibility ...
Source: Journal of Microbiological Methods - Category: Microbiology Source Type: research
More News: Clinical Trials | Hospitals | Respiratory Medicine | Study